MUC1

PDC*line Pharma Completes Enrolment of Four Cohorts of Patients in PDC-LUNG-101 Phase I/II Clinical Trial

Retrieved on: 
Wednesday, December 6, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Data, Safety, NY-ESO-1, Non-small-cell lung cancer, Clinical trial, ESMO, Patient, DSMB, Pembrolizumab, MUC1, PD-1, MAGE, Dendritic cell, Cancer, PDC, KU Leuven, Mutation, Pharmaceutical industry, Vaccine, NSCLC

The objectives of the phase I/II trial (PDC-LUNG-101) were to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients.

Key Points: 
  • The objectives of the phase I/II trial (PDC-LUNG-101) were to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients.
  • The trial was conducted at 17 clinical sites in France, Belgium, Germany, the Netherlands and Poland.
  • “We are pleased to have achieved full patient enrolment in the PDC-LUNG-101 clinical trial, a key step in the product’s clinical development and another important milestone for PDC*line Pharma.
  • “I would like to extend my gratitude to the investigators and patients across the five countries included in our clinical trial.

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Triple-negative breast cancer, Society, Euronext Growth, San Diego Convention Center, SITC, Immunotherapy, PDT, EDT, CAR, Journal, JITC, Poster, MUC1, Vaccine, Cellectis

Laurent Poirot, SVP Immunology of Cellectis, will present a poster on the benefits of combining potency attributes for TALEN®-edited smart CAR T-cells targeting MUC1 in preclinical models of triple-negative breast cancer.

Key Points: 
  • Laurent Poirot, SVP Immunology of Cellectis, will present a poster on the benefits of combining potency attributes for TALEN®-edited smart CAR T-cells targeting MUC1 in preclinical models of triple-negative breast cancer.
  • Title: TGF-Beta Blockade Combined with Activation-Induced IL12 Secretion Synergize to Optimize Potency of MUC1-CAR T-cells in Preclinical Targeting of Triple-Negative Breast Cancer.
  • Date/Time: Poster will be on display Saturday, November 4th, 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.
  • Full text of the abstract will be made public on October 31, 2023 at 9:00 a.m. EDT on the SITC website and in a Journal for ImmunoTherapy of Cancer (JITC) supplement published on Oct. 31st, 2023 at 6 a.m. PDT/9 a.m. EDT.

CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer

Retrieved on: 
Monday, August 21, 2023
Pancreatic cancer, Marketing, ODD, Cancer, Malignancy, Patient, MUC1, Diagnosis, Rare, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Vaccine, Pharmaceutical industry

PYEONGTAEK, South Korea, Aug. 21, 2023 /PRNewswire/ -- CanariaBio Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immunotherapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its investigational drug product, MAb-AR20.5, an IgG1k type murine monoclonal antibody that binds specifically to the circulating and tumor-associated antigen (MUC1) expressed ubiquitously on pancreatic cancer cells. This milestone marks the first monoclonal antibody targeting Mucin 1 (MUC1) to receive this designation for pancreatic cancer.

Key Points: 
  • This milestone marks the first monoclonal antibody targeting Mucin 1 (MUC1) to receive this designation for pancreatic cancer.
  • Pancreatic cancer remains one of the most challenging malignancies to treat, with limited therapeutic options available.
  • The MAb-AR20.5 has shown potential in early studies, by inducing MUC-1-specific immune responses in cancer patients with advanced disease.
  • CanariaBio Inc. is planning to initiate clinical trials to assess the safety and efficacy of MAb-AR20.5 in patients with pancreatic cancer.

Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 17, 2023
TNBC, AACR, Euronext Growth, Senior, American Association for Cancer Research, Breast, Cancer, CAR, Patient, MUC1, Neoplasm, Glycosylation, Vaccine, Cellectis

Tumor-associated MUC1 antigen is overexpressed in a large number of TNBC patients offering an effective discriminatory target for CAR T-cell therapy.

Key Points: 
  • Tumor-associated MUC1 antigen is overexpressed in a large number of TNBC patients offering an effective discriminatory target for CAR T-cell therapy.
  • Cellectis’ MUC1 CAR T-cells are allogeneic and target Mucin 1 for TNBC and a variety of epithelial cancers.
  • Additionally, MUC1 heavy glycosylation in normal tissue contrasts with Cellectis’ MUC1 CAR that is designed to recognize hypoglycosylated MUC1 present in cancer cells.
  • Thus, innovative strategies can be used to allow CAR T-cell efficiency in the hostile tumor microenvironment while preserving safety.

Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, March 14, 2023
Tumor microenvironment, AACR, MUC1, Annual general meeting, Prognosis, CAR, Senior, TGFB1, Patient, Triple-negative breast cancer, Breast, TNBC, TME, Euronext Growth, American Association for Cancer Research, Vaccine, Medical imaging, Cellectis

“As immune-therapies continue to develop for solid tumors, the tumor microenvironment (TME) poses many challenges that CAR T-cells need to overcome for efficient tumor cell clearance.

Key Points: 
  • “As immune-therapies continue to develop for solid tumors, the tumor microenvironment (TME) poses many challenges that CAR T-cells need to overcome for efficient tumor cell clearance.
  • Tumor-associated MUC1 antigen is overexpressed in a large number of TNBC patients offering an effective discriminatory target for CAR T-cell therapy.
  • Cellectis will present innovative strategies exploring purposeful armoring of CAR T-cells to boost efficiency while preserving safety.
  • The recirculation pattern of MUC1 CAR T-cells was also explored in relationship with their delivery routes.

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

Retrieved on: 
Wednesday, March 8, 2023
Immunotherapy, Stanford University, Literature, Bone marrow, Therapy, Laboratory, University of Pennsylvania, Oncology, SAB, BS, Memorial Sloan Kettering Cancer Center, Internal medicine, Patient, Pharmacology, Translation, MUC1, Fordham University, United States Air Force Scientific Advisory Board, MD, ETH Zurich, Massachusetts Institute of Technology, Harvard Medical School, Cell, History of the University of Maryland, College Park, University, Biosensor, Harvard University, Doctor of Philosophy, Glycosylation, Chromatin, NF-κB, LSE, Research, Hematology, CAR, Cell engineering, UMBC, Aptamer, Management, Vaccine, Biology, Genetics, Medicine, Chemistry, Biochemistry

“With the formation of our Scientific Advisory Board, we are expanding the depth and breadth of our leadership team and scientific expertise with the next generation of leaders in the field of gene and cell therapy,” said Doug Doerfler, President and CEO of MaxCyte.

Key Points: 
  • “With the formation of our Scientific Advisory Board, we are expanding the depth and breadth of our leadership team and scientific expertise with the next generation of leaders in the field of gene and cell therapy,” said Doug Doerfler, President and CEO of MaxCyte.
  • Supported by deep technical knowledge, the SAB will help us unlock the power of cells, which will enhance our R&D activities and portfolio,” said Cenk Sumen, PhD, Chief Scientific Officer of MaxCyte.
  • Dr. Maus holds graduate degrees (M.D., Ph.D.) from University of Pennsylvania, where she completed graduate training with Dr. Carl June.
  • Her thesis exploited aptamers to overcome the conventional bottlenecks of electronic biosensing of small molecules in complex biological environments.

Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers

Retrieved on: 
Tuesday, January 31, 2023
Inflammation, CSCS, Cancer, SCLC, MUC1, NEPC, Iron, Ferroptosis, Drug resistance, Dana–Farber Cancer Institute, Hitachi HD44780 LCD controller, TNBC, CSC, Immunosuppression, Cell death, Pharmaceutical industry, Vaccine, Hillstream loach

BRIDGEWATER, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced signing an exclusive option agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein.

Key Points: 
  • The MUC1 gene was identified by Dr. Donald Kufe, Distinguished Physician and Researcher at Dana-Farber and based on its overexpression in human cancers.
  • Dr. Kufe’s long-standing work has supported the premise that prolonged activation of MUC1-C in settings of chronic inflammation promotes cancer.
  • “We look forward to this unique opportunity to work with Dr. Kufe and Dana-Farber,” said Randy Milby, CEO of Hillstream.
  • “This agreement allows Hillstream to leverage our Quatramer platform to advance anti-MUC1-C agents targeting CSCs for the treatment of highly aggressive tumors, which represents a major unmet need for patients.”

Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor Cancers

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, Clinical trial, Investigational New Drug, Progressive disease, Courage, Phosphorylation, Metastasis, CAR, Growth, Patient, Tyrosine, MUC1, FDA, IND, Recurrence, Biotechnology, Partial-response maximum-likelihood, Memorial Sloan Kettering Cancer Center, Pharmaceutical industry, Vaccine, Phenylalanine

huMNC2-CAR22 targets MUC1* (muk 1 star), the growth factor receptor that drives the growth and metastasis of most solid tumor cancers.

Key Points: 
  • huMNC2-CAR22 targets MUC1* (muk 1 star), the growth factor receptor that drives the growth and metastasis of most solid tumor cancers.
  • Minerva’s first CAR T that targets MUC1*, huMNC2-CAR44, is already in a clinical trial for metastatic breast cancers.
  • However, for a durable response, we needed to overcome CAR T cell exhaustion, which is common to CAR T cell treatment of solid tumor cancers.
  • Unexpectedly, the 1XX mutations give the CAR T cells the added benefit of being able to recognize and kill the low antigen expressing cancer cells that lead to cancer recurrence.

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer

Retrieved on: 
Tuesday, December 13, 2022
NK, Neoplasm, CDO, Triple-negative breast cancer, Safety, Gene editing, Enhance, TNBC, IPSC, MUC1, Antigen, Risk, Patient, Pharmaceutical industry, Medical imaging, Vaccine

Inc, Therabest Korea (Therabest) and Glycotope GmbH (Glycotope) have signed an agreement to assess the clinical development of Therabest’s EiNKTM (Enhanced iPSC-derived NK) cell therapy, TB-100, in combination with Glycotope’s immuno-cytokine, GT-00AxIL15 in triple-negative breast cancer (TNBC) patients.

Key Points: 
  • Inc, Therabest Korea (Therabest) and Glycotope GmbH (Glycotope) have signed an agreement to assess the clinical development of Therabest’s EiNKTM (Enhanced iPSC-derived NK) cell therapy, TB-100, in combination with Glycotope’s immuno-cytokine, GT-00AxIL15 in triple-negative breast cancer (TNBC) patients.
  • NK cell therapies from various cell sources have demonstrated exciting results in early clinical trials and are rapidly becoming powerful alternatives to conventional treatments.
  • However, for solid tumors, NK cell therapies are still hampered by the low persistency and homing of NK cells.
  • TB-100, a highly active NK cell therapy development candidate from EiNKTM platform, can recognize and remove heterogeneous cancer cells very effectively.

PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022

Retrieved on: 
Friday, December 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Memory, Peptide, Melanoma, Blood bank, PBMC, HLA-A2, B cell, Antigen, Large-cell lung carcinoma, NK, Poster, MUC1, Patient, NY-ESO-1, PDC, Lung cancer, Hlas, GMP, Non-small-cell lung carcinoma, PD-1, RECIST, White blood cell, Safety, Cancer, Dendritic cell, ESMO, Human, RNA transfection, LOQ, Clinical trial, Growth, Bioreactor, MAGE, EFS, Pembrolizumab, Mutation, Pharmaceutical industry, Vaccine, NSCLC

The preliminary data was presented today at a poster display session at the ESMO Immuno-Oncology Congress 2022 (ESMO-IO) in Geneva (Switzerland).

Key Points: 
  • The preliminary data was presented today at a poster display session at the ESMO Immuno-Oncology Congress 2022 (ESMO-IO) in Geneva (Switzerland).
  • The objectives of the phase I/II trial (PDC-LUNG-101) are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients.
  • It is administered weekly by a subcutaneous and intravenous route, in six consecutive doses.
  • Safety and clinical activity of the product were presented at ESMO 2022 in September 2022 in Paris (France).